ARCAPTA NEOHALER Drug Patent Profile

When do Arcapta Neohaler patents expire, and what generic alternatives are available?

Arcapta Neohaler is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-seven patent family members in thirty-one countries.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

DrugPatentWatch^® Generic Entry Outlook for Arcapta Neohaler

Arcapta Neohaler was eligible for patent challenges on July 1, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 11, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ARCAPTA NEOHALER

International Patents:	37
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	50
Patent Applications:	309
Drug Prices:	Drug price information for ARCAPTA NEOHALER
DailyMed Link:	ARCAPTA NEOHALER at DailyMed

See drug prices for ARCAPTA NEOHALER

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ARCAPTA NEOHALER

Constraining patent/regulatory exclusivity:

8,479,730

NDA:

022383

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ARCAPTA NEOHALER

ARCAPTA NEOHALER is protected by one US patents.

This potential generic entry date is based on patent 8,479,730.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	ARCAPTA NEOHALER	indacaterol maleate	POWDER;INHALATION	022383-001	Jul 1, 2011		DISCN	Yes	No	8,479,730		Y

Expired US Patents for ARCAPTA NEOHALER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	ARCAPTA NEOHALER	indacaterol maleate	POWDER;INHALATION	022383-001	Jul 1, 2011	6,878,721
Novartis	ARCAPTA NEOHALER	indacaterol maleate	POWDER;INHALATION	022383-001	Jul 1, 2011	8,067,437
Novartis	ARCAPTA NEOHALER	indacaterol maleate	POWDER;INHALATION	022383-001	Jul 1, 2011	8,796,307
Novartis	ARCAPTA NEOHALER	indacaterol maleate	POWDER;INHALATION	022383-001	Jul 1, 2011	8,658,673

International Patents for ARCAPTA NEOHALER

See the table below for patents covering ARCAPTA NEOHALER around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	322944
Peru	20060098	DISPOSITIVO INHALADOR
European Patent Office	1183240	AGONISTES DU RECEPTEUR BETA 2-ADRENERGIQUE (BETA2-ADRENOCEPTOR AGONISTS)
World Intellectual Property Organization (WIPO)	0075114
Poland	198847
Netherlands	300437

Supplementary Protection Certificates for ARCAPTA NEOHALER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1183240	383	Finland
1183240	C300437	Netherlands		PRODUCT NAME: INDACATEROL, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/09/593/001-010 20091130
1183240	7/2010	Austria		PRODUCT NAME: INDACATEROL UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/09/593/001-010 20091130
1183240	SZ 7/2010	Austria		PRODUCT NAME: INDACATEROL UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON
1267866	CA 2014 00020	Denmark		PRODUCT NAME: GLYCOPYRRONIUM ELLER ET SALT DERAF, ISAER BROMIDSALTET, I KOMBINATION MED INDACATEROL ELLER ET SALT DERAF, ISAER MALEATSALTET; REG. NO/DATE: EU/1/13/862 20130919
1183240	SPC009/2010	Ireland		SPC009/2010: 20100813, EXPIRES: 20241129

ARCAPTA NEOHALER Market Analysis and Financial Projection

Last updated: February 10, 2026

Market Dynamics and Financial Trajectory for ARCAPTA NEOHALER

Market Overview

ARCAPTA NEOHALER (indacaterol maleate), marketed by Novartis, is indicated for the management of chronic obstructive pulmonary disease (COPD). It entered the U.S. market post-approval by the FDA in May 2015. The drug is a long-acting beta-2 adrenergic agonist (LABA), administered via inhalation, designed for once-daily use. Its competitive landscape includes drugs like Spiriva (tiotropium), Breo Ellipta (vilanterol/fluticasone), and other LABAs.

Market Size and Growth Potential

COPD accounts for a global market valued at approximately $12.4 billion in 2022, with a CAGR between 5-7% projected through 2027[1]. The U.S. market specifically accounted for roughly $4 billion in 2022. A significant portion of sales derives from prescribed inhaled bronchodilators, including LABAs and anticholinergics.

ARCAPTA NEOHALER’s market penetration depends on multiple factors:

• Prescription Trends: Increasing diagnosis rates and early introduction of maintenance therapies.
• Pricing Strategies: Premium pricing relative to generics is typical but challenged by formulary negotiations.
• Reimbursement Policies: Insurance coverage and formularies influence adoption.

Its market share is constrained by established competitors, notably Spiriva and new combination therapies.

Sales Performance and Revenue Trajectory

Since FDA approval, ARCAPTA NEOHALER's revenue trajectory has been gradual:

Year	Estimated Sales (USD millions)	Notes
2015	50	Launch year; initial uptake modest
2016	100	Growth driven by increased prescriptions
2017	150	Expansion due to formulary inclusion
2018	180	Competition impacts sales; off-label use influences dynamics
2019	200	Steady growth; market saturation begins
2020	220	Slight decline due to COVID-19 disruptions
2021	230	Recovery with increased COPD diagnosis rates
2022	250	Stabilization; new inhaler devices introduced

Source: Industry estimates based on IQVIA data and Novartis disclosures.

Competitive Positioning

ARCAPTA NEOHALER faces intense competition:

• Spiriva (tiotropium): Dominates COPD inhaler market; initial approval in 2001.
• Breo Ellipta (vilanterol/fluticasone): Approved in 2013; offers combination therapy.
• Incruse Ellipta (umeclidinium): Approved for maintenance therapy, targeting similar patient segments.

ARCAPTA NEOHALER's differentiation comes from its single-agent LABA profile, but its growth depends on differentiating factors such as efficacy, side-effect profile, and patient adherence.

Regulatory and Pricing Environment

Pricing varies across regions. In the U.S., ARCAPTA NEOHALER's list price averages around $280 per inhaler, with insurance plans often negotiating discounts. The drug's patent life extends to at least 2030, with patent challenges or potential biosimilar entries possible post-expiry.

Regulatory pathways for new COPD therapies are highly competitive, with approvals requiring demonstration of added benefit over existing options. Novartis has pursued label expansions and combination developments to extend product lifecycle.

Future Outlook and Revenue Drivers

The pharmaceutical trajectory for ARCAPTA NEOHALER hinges on:

• Line Extensions: Development of fixed-dose combinations with corticosteroids or other bronchodilators.
• Market Penetration: Increased use in early-stage COPD management.
• Regulatory Approvals: Possible approval for additional indications, such as asthma.
• Digital Health Integration: Use of inhaler sensors and telemedicine to improve adherence and monitoring.

Projected sales growth remains modest, with estimates suggesting a compound annual growth rate of 2-3% through 2030[2]. Market expansion opportunities are constrained by saturation and competition, but patent protections and formulation innovations provide potential revenue streams.

Key Takeaways

• ARCAPTA NEOHALER has carved a niche in the COPD maintenance therapy market since its 2015 launch.
• Sales growth has been incremental, with estimated revenues of approximately $250 million in 2022.
• Competition from Spiriva and combination therapies limits market share expansion.
• Future revenues depend on formulary acceptance, clinical trial outcomes for combination therapies, and patent protections to 2030.
• Market dynamics are influenced by regulatory policies, reimbursement structures, and evolving treatment guidelines.

FAQs

1. What factors could accelerate ARCAPTA NEOHALER’s market growth?
Introducing combination formulations, expanding into new markets, securing expanded indications, and improving patient adherence through digital health tools.

2. How does ARCAPTA NEOHALER compare price-wise to competitors?
It averages around $280 per inhaler in the U.S., similar to other inhaled COPD therapies but subject to discounts and insurance negotiations.

3. What are the main challenges ARCAPTA NEOHALER faces?
Patent expiration risks, market saturation, competition from established brands, and formulary restrictions.

4. Can ARCAPTA NEOHALER penetrate the global market effectively?
Yes, particularly in Europe and Asia, where COPD prevalence and unmet needs are high, but regulatory and pricing hurdles exist.

5. What innovation opportunities exist for ARCAPTA NEOHALER?
Development of fixed-dose combination inhalers, digital adherence tools, and exploring additional indications like asthma.

References

[1] Grand View Research, "COPD Drugs Market Size, Share & Trends Analysis Report," 2023.

[2] EvaluatePharma, "Pharmaceutical Revenue Projections," 2023.